PSI-6130

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark.^[1] Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B.^[2]

PSI-6130

Clinical data
ATC code	none
Identifiers
IUPAC name 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
CAS Number	817204-33-4 Y
PubChem CID	6481236
ChemSpider	4981776
UNII	05J68784G1
ChEMBL	ChEMBL223482
CompTox Dashboard (EPA)	DTXSID10231287
Chemical and physical data
Formula	C10H14FN3O4
Molar mass	259.237 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
InChI InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1 Key:NYPIRLYMDJMKGW-VPCXQMTMSA-N
(verify)

PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128.^[3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.^[4]